Bioventus (BVS) Cash from Operations (2020 - 2026)

Bioventus (BVS) has reported Cash from Operations for 7 consecutive years, with $19.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations fell 23.38% year-over-year to $19.9 million; the trailing twelve-month figure through Jun 2026 stood at $96.9 million (up 167.27% YoY), and the FY2025 full-year result was $74.7 million, up 92.48% from the prior year.
• Cash from Operations improved to $19.9 million in Q2 2026 per BVS's latest filing, from $8.9 million in the prior quarter.
• Across five years, Cash from Operations topped out at $38.0 million in Q4 2025 and bottomed at -$21.0 million in Q2 2022.
• Historically, Cash from Operations has averaged $8.1 million across 5 years, with a median of $9.6 million in 2024.
• The widest YoY moves for Cash from Operations: up 267.3% in 2023, down 1086.16% in 2023.
• Over 5 years, Cash from Operations stood at $5.2 million in 2022, then jumped by 97.83% to $10.4 million in 2023, then surged by 86.25% to $19.3 million in 2024, then surged by 96.5% to $38.0 million in 2025, then sank by 47.66% to $19.9 million in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered $19.9 million, $8.9 million, and $38.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.